On Invalid Date, Gain Therapeutics (NASDAQ: GANX) reported Q4 2023 earnings per share (EPS) of -$0.29, up 25.64% year over year. Total Gain Therapeutics earnings for the quarter were -$4.72 million. In the same quarter last year, Gain Therapeutics's earnings per share (EPS) was -$0.39.
As of Q1 2024, Gain Therapeutics's earnings has grown year over year. Gain Therapeutics's earnings in the past year totalled -$22.27 million.
What is GANX's earnings date?
Gain Therapeutics's earnings date is Invalid Date. Add GANX to your watchlist to be reminded of GANX's next earnings announcement.
What was GANX's revenue last quarter?
On Invalid Date, Gain Therapeutics (NASDAQ: GANX) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Gain Therapeutics's revenue was $0.00.
What was GANX's revenue growth in the past year?
As of Q1 2024, Gain Therapeutics's revenue has grown -60.62% year over year. This is 226.23 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Gain Therapeutics's revenue in the past year totalled $55.18 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.